Gain Therapeutics Inc
gaintherapeutics.comGain Therapeutics Inc (NASDAQ: GANX) is a biotechnology company developing small molecule therapeutics to treat diseases through molecular chaperoning, protein stabilization, and protein modulation. The company generates no product revenue and finances operations through equity offerings, including a June 2024 public offering of 7.1 million shares and 1.0 million pre-funded warrants at $1.35 per share that produced $11.0 million in gross proceeds, and a 2024 at-the-market program that provided $3.0 million in net proceeds. Gain Therapeutics has no products approved for commercial sale and directs spending toward preclinical and clinical research across central nervous system disorders, lysosomal storage disorders, metabolic disorders, and oncology. The company has never declared or paid a cash dividend and does not intend to do so. As of the 10-K filed March 26, 2026, the company remains pre-revenue and dependent on external financing to fund operations.
Products & Services
Small molecule drug candidates targeting misfolded proteins via molecular chaperoning, aimed at central nervous system disorders, lysosomal storage disorders, metabolic disorders, and oncology. All programs are in preclinical or clinical development stages as of the 10-K filed March 26, 2026.
Revenue Model
No product revenue as of the fiscal year ended December 31, 2025. Operations are funded through equity offerings and at-the-market programs. The company has not generated substantial product revenue and may seek future collaboration or licensing arrangements.
Customers & Markets
No commercial customers as of the fiscal year ended December 31, 2025. Target end markets include CNS disorders, lysosomal storage disorders, metabolic disorders, and oncology.
Geographic Exposure
Headquartered in the United States. Conducts research collaborations with third parties including international partners. Subject to data privacy regulations across the United States, European Economic Area, United Kingdom, and Switzerland.
Financial Snapshot
Loading...
